Karl Johe - curasan AG Insider

CUR -- Germany Stock  

EUR 0.87  0.04  4.40%

Chairman of the Board, Chief Scientific Officer

Dr. Karl Johe Ph.D. is Chairman of the Board and Chief Scientific Officer of Neuralstem Inc. since 1996. Dr. Johe has over 15 years of research and laboratory experience. Dr. Johe is the sole inventor of Neuralstems granted stem cell patents and is responsible for the strategic planning and development of our therapeutic products. Dr. Johe received his Bachelor of Arts Degree in Chemistry and a Masters Degree from the University of Kansas. Dr. Johe received his doctorate from the Albert Einstein College of Medicine of Yeshiva University. From 1993 to January 1997 Dr. Johe served as a Staff Scientist at the Laboratory of Molecular Biology of the National Institute of Neurological Disease and Stroke in Bethesda Maryland. While holding this position Dr. Johe conducted research on the isolation of neural stem cells the elucidation of mechanisms directing cell type specification of central nervous system stem cells and the establishment of an in vitro model of mammalian neurogenesis. In evaluating Dr. Johes specific experience qualifications attributes and skills in connection with his appointment to our board we took into account his extensive experience in international science and business communities. Dr. Johe is also multilingual.
Age: 53  Chairman Since 1996      
49 6027 40 900 51  http://www.curasan.de
Johe received his doctorate from the Albert Einstein College of Medicine of Yeshiva University. From 1993 to January 1997, Dr. Johe served as a Staff Scientist at the Laboratory of Molecular Biology of the National Institute of Neurological Disease and Stroke in Bethesda, Maryland. While holding this position, Dr. Johe conducted research on the isolation of neural stem cells, the elucidation of mechanisms directing cell type specification of central nervous system stem cells and the establishment of an in vitro model of mammalian neurogenesis.

Karl Johe Latest Insider Activity

Karl Johe over three months ago via Macroaxis 
Sale by Karl Johe of 25000 shares of Neuralstem

Management Efficiency

The company has return on total asset (ROA) of (13.06) % which means that it has lost $13.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (42.32) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 265 K in total debt with debt to equity ratio (D/E) of 2.6 implying the company greatly relies on financing operations through barroing. curasan AG has Current Ratio of 2.1 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company was founded in 1988 and is based in Kleinostheim, Germany. curasan AG operates under Healthcare Products classification in Germany and traded on Frankfurt Stock Exchange.curasan AG (CUR) is traded on Frankfurt Stock Exchange in Germany. It is located in Lindigstrasse 4 and employs 36 people.

curasan AG Leadership Team

William Oldaker, Director
David Castaneda, Executive
Stanley Westreich, Director
Karl Johe, Chairman
Scott Ogilvie, Director
Catherine Sohn, Director, Ph.D
Richard Garr, CEO
Richard Daly, CEO, MBA
Sandford Smith, Director
Jonathan Jones, CFO

Stock Performance Indicators

Did you try this?

Run Portfolio Quick Import Now
   

Portfolio Quick Import

Import or update all your transactions via one easy-to-use interface
All  Next Launch Portfolio Quick Import

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for curasan AG and Fielmann AG. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.